Sun Pharma Advanced Research Company announced the signing of a binding Letter of Intent (LOI) with the University of California, San Francisco (UCSF), through the office of OTMA, and Tiller Therapeutics Inc. (Tiller) to license SPARC`s rights in the joint intellectual property (IP) held between SPARC and UCSF for pre-clinical oncology asset along with associated IP. The LOI outlines the key terms of license and rights for development and commercialization by Tiller.Under the terms of the LOI, SPARC will receive 55% equity stake in Tiller upon execution of LOI. The equity will vest in two tranches; 45% equity will vest upon execution of license agreement and the remaining 10% equity will vest at the earlier of achievement of certain milestones by Tiller or within 6 months of execution of license agreement. Other terms of the license will be outlined in the license agreement.Powered by Capital Market - Live News

Net Loss of Sun Pharma Advanced Research Company reported to Rs 107.33 crore in the quarter ended September 2024 as against net loss of Rs 86.42 crore during the previous quarter ended September 2023. Sales declined 39.28% to Rs 12.86 crore in the quarter ended September 2024 as against Rs 21.18 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales12.8621.18 -39 OPM %-800.23-431.87 - PBDT-104.01-83.24 -25 PBT-107.17-86.42 -24 NP-107.33-86.42 -24 Powered by Capital Market - Live News

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 4 November 2024Powered by Capital Market - Live News

Net Loss of Sun Pharma Advanced Research Company reported to Rs 95.90 crore in the quarter ended June 2024 as against net loss of Rs 95.35 crore during the previous quarter ended June 2023. Sales declined 29.81% to Rs 16.81 crore in the quarter ended June 2024 as against Rs 23.95 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales16.8123.95 -30 OPM %-555.38-426.64 - PBDT-92.36-92.25 0 PBT-95.50-95.35 0 NP-95.90-95.35 -1 Powered by Capital Market - Live News

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 5 August 2024.Powered by Capital Market - Live News